Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2018

01-05-2018 | Brief Report

Patient-reported outcomes of catheter-based accelerated partial breast brachytherapy and whole breast irradiation, a single institution experience

Authors: Krishan R. Jethwa, Mohamed M. Kahila, Kristin C. Mara, William S. Harmsen, David M. Routman, Geralyn M. Pumper, Kimberly S. Corbin, Jeff A. Sloan, Kathryn J. Ruddy, Tina J. Hieken, Sean S. Park, Robert W. Mutter

Published in: Breast Cancer Research and Treatment | Issue 1/2018

Login to get access

Abstract

Purpose

Accelerated partial breast irradiation (APBI) and whole breast irradiation (WBI) are treatment options for early-stage breast cancer. The purpose of this study was to compare patient-reported-outcomes (PRO) between patients receiving multi-channel intra-cavitary brachytherapy APBI or WBI.

Methods

Between 2012 and 2015, 131 patients with ductal carcinoma in situ (DCIS) or early stage invasive breast cancer were treated with adjuvant APBI (64) or WBI (67) and participated in a PRO questionnaire. The linear analog scale assessment (LASA), harvard breast cosmesis scale (HBCS), PRO-common terminology criteria for adverse events- PRO (PRO-CTCAE), and breast cancer treatment outcome scale (BCTOS) were used to assess quality of life (QoL), pain, fatigue, aesthetic and functional status, and breast cosmesis. Comparisons of PROs were performed using t-tests, Wilcoxon rank-sum, Chi square, Fisher exact test, and regression methods.

Results

Median follow-up from completion of radiotherapy and questionnaire completion was 13.3 months. There was no significant difference in QoL, pain, or fatigue severity, as assessed by the LASA, between treatment groups (p > 0.05). No factors were found to be predictive of overall QoL on regression analysis. BCTOS health-related QoL scores were similar between treatment groups (p = 0.52).The majority of APBI and WBI patients reported excellent/good breast cosmesis, 88.5% versus 93.7% (p = 0.37). Skin color change (p = 0.011) and breast elevation (p = 0.01) relative to baseline were more common in the group receiving WBI.

Conclusions

APBI and WBI were both associated with favorable patient-reported outcomes in early follow-up. APBI resulted in a lesser degree of patient-reported skin color change and breast elevation relative to baseline.
Appendix
Available only for authorised users
Literature
1.
Clarke M et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087–2106CrossRefPubMed
2.
Correa C et al (2017) Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol 7(2):73–79CrossRefPubMed
3.
Institute, N.C., NSABP B-39: A randomized phase iii study of conventional whole breast irradiation (wbi) versus partial breast irradiation (pbi) for women with stage 0, I, or II breast CANCER
4.
Livi L et al (2015) Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer 51(4):451–463CrossRefPubMed
5.
Strnad V et al (2016) 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet 387(10015):229–238CrossRefPubMed
6.
Bitter SM et al (2016) WBRT versus APBI: an interim report of patient satisfaction and outcomes. J Contemp Brachyther 8(1):17–22CrossRef
7.
Garsa AA et al (2013) A prospective longitudinal clinical trial evaluating quality of life after breast-conserving surgery and high-dose-rate interstitial brachytherapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys 87(5):1043–1050CrossRefPubMedPubMedCentral
8.
He ZY et al (2012) A comparison of quality of life of early breast cancer patients treated with accelerated partial breast irradiation versus whole breast irradiation in China. Breast Cancer Res Treat 133(2):545–552CrossRefPubMed
9.
Marta GN et al (2015) Accelerated partial irradiation for breast cancer: systematic review and meta-analysis of 8653 women in eight randomized trials. Radiother Oncol 114(1):42–49CrossRefPubMed
10.
Meattini I et al (2017) Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. Eur J Cancer 76:17–26CrossRefPubMed
11.
Perrucci E et al (2015) Quality of life and cosmesis after breast cancer: whole breast radiotherapy versus partial breast high-dose-rate brachytherapy. Tumori 101(2):161–167CrossRefPubMed
12.
Wadasadawala T et al (2009) Quality of life after accelerated partial breast irradiation in early breast cancer: matched pair analysis with protracted whole breast radiotherapy. Clin Oncol 21(9):668–675CrossRef
13.
Perez M et al (2017) Accelerated partial breast irradiation compared with whole breast radiation therapy: a breast cancer cohort study measuring change in radiation side-effects severity and quality of life. Breast Cancer Res Treat 162(2):329–342CrossRefPubMedPubMedCentral
14.
Olivotto IA et al (2013) Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol 31(32):4038–4045CrossRefPubMed
15.
16.
Vaidya JS et al (2010) Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet 376(9735):91–102CrossRefPubMed
17.
Veronesi U et al (2013) Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol 14(13):1269–1277CrossRefPubMed
18.
Harris JR et al (1979) Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast. Int J Radiat Oncol Biol Phys 5(2):257–261CrossRefPubMed
19.
Krishnan L et al (2001) Form or function? Part 2. Objective cosmetic and functional correlates of quality of life in women treated with breast-conserving surgical procedures and radiotherapy. Cancer 91(12):2282–2287CrossRefPubMed
20.
Stanton AL, Krishnan L, Collins CA (2001) Form or function? part 1. subjective cosmetic and functional correlates of quality of life in women treated with breast-conserving surgical procedures and radiotherapy. Cancer 91(12):2273–2281CrossRefPubMed
21.
Hieken TJ et al (2016) A novel treatment schedule for rapid completion of surgery and radiation in early-stage breast cancer. Ann Surg Oncol 23(10):3297–3303CrossRefPubMed
22.
Remouchamps VM et al (2003) Significant reductions in heart and lung doses using deep inspiration breath hold with active breathing control and intensity-modulated radiation therapy for patients treated with locoregional breast irradiation. Int J Radiat Oncol Biol Phys 55(2):392–406CrossRefPubMed
23.
Polgar C et al (2017) Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncol 18(2):259–268CrossRefPubMed
24.
Rabinovitch R et al (2016) Long-term update of nrg oncology rtog 0319: a phase 1 and 2 trial to evaluate 3-dimensional conformal radiation therapy confined to the region of the lumpectomy cavity for stage 1 and 2 breast carcinoma. Int J Radiat Oncol Biol Phys 96(5):1054–1059CrossRefPubMedPubMedCentral
25.
Shaitelman SF et al (2017) American brachytherapy society task group report: long-term control and toxicity with brachytherapy for localized breast cancer. Brachytherapy 16(1):13–21CrossRefPubMed
26.
Baruch Y, Holtom BC (2008) Survey response rate levels and trends in organizational research. Hum Relat 61(8):1139–1160CrossRef
27.
Metadata
Title
Patient-reported outcomes of catheter-based accelerated partial breast brachytherapy and whole breast irradiation, a single institution experience
Authors
Krishan R. Jethwa
Mohamed M. Kahila
Kristin C. Mara
William S. Harmsen
David M. Routman
Geralyn M. Pumper
Kimberly S. Corbin
Jeff A. Sloan
Kathryn J. Ruddy
Tina J. Hieken
Sean S. Park
Robert W. Mutter
Publication date
01-05-2018
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4665-6

Other articles of this Issue 1/2018

Breast Cancer Research and Treatment 1/2018 Go to the issue

Epidemiology

Surveillance for cancer recurrence in long-term young breast cancer survivors randomly selected from a statewide cancer registry

Epidemiology

Living with chronic pain: perceptions of breast cancer survivors

Epidemiology

Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence

Review

Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG)

Preclinical study

Impact of an embedded genetic counselor on breast cancer treatment

Preclinical study

The PPARγ agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits